Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fletcher RE, Nunes NS, Patterson MT, Vinod N, Khan SM, Mendu SK, et al. Posttransplantation cyclophosphamide expands functional myeloid-derived suppressor cells and indirectly influences Tregs. Blood Adv. 2023;7:1117–29.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moiseev IS, Pirogova OV, Alyanski AL, Babenko EV, Gindina TL, Darskaya EI, et al. Graft-versus-host disease prophylaxis in unrelated peripheral blood stem cell transplantation with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil. Biol Blood Marrow Transplant. 2016;22:1037–42.

Article  CAS  PubMed  Google Scholar 

Brissot E, Labopin M, Moiseev I, Cornelissen J, Meijer E, Van Gorkom G, et al. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors. J Hematol Oncol. 2020;13:1–10.

Article  Google Scholar 

Jimenez Jimenez A, Komanduri K, Brown S, Wang T, Pereira D, Goodman M, et al. Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant. Blood Adv. 2022;6:4491–500.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salas MQ, Eikema D-J, Koster L, Maertens J, Passweg J, Finke J, et al. Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant. 2024;59:1–10.

Battipaglia G, Labopin M, Kröger N, Vitek A, Afanasyev B, Hilgendorf I, et al. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood, J Am Soc Hematol. 2019;134:892–9.

CAS  Google Scholar 

Gao F, Zhang J, Hu J, Lin L, Xu Y. Post-transplant cyclophosphamide versus antithymocyte globulin in allogeneic hematopoietic cell transplantation: a meta-analysis. Ann Hematol. 2021;100:529–40.

Article  CAS  PubMed  Google Scholar 

Leserer S, Graf T, Franke M, Bogdanov R, Arrieta-Bolaños E, Buttkereit U, et al. Time series clustering of T cell subsets dissects heterogeneity in immune reconstitution and clinical outcomes among MUD-HCT patients receiving ATG or PTCy. Front Immunol. 2023;14:1082727.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, et al. Phase II trial of graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide after reduced-intensity busulfan/fludarabine conditioning for hematological malignancies. Biol Blood Marrow Transplant. 2015;21:906–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pedraza A, Jorge S, Suárez-Lledó M, Pereira A, Gutiérrez-García G, Fernández-Avilés F, et al. High-dose cyclophosphamide and tacrolimus as graft-versus-host disease prophylaxis for matched and mismatched unrelated donor transplantation. Transpl Cell Ther. 2021;27:619.e611–619.e618. https://doi.org/10.1016/j.jtct.2021.03.022.

Article  CAS  Google Scholar